Novartis Venture Fund co-led the gene therapy developer's series A round, raised as it prepares to submit an investigational new drug application for its lead drug.
Renovacor, a US-based gene therapy spinout of Temple University focused on cardiovascular disease, closed an $11m series A round yesterday co-led by Novartis Venture Fund, a corporate venturing subsidiary of pharmaceutical firm Novartis.
The round was co-led by venture capital firm BioAdvance and Broadview Ventures, a cardiovascular-focused impact investment vehicle formed by family office Leducq Family Trust, while New Leaf Venture Partners and Innogest Capital also invested.
Renovacor is looking to commercialise a drug for dilated cardiomyopathy (DCM), a serious…
